BioFocus has signed a collaboration agreement with Astellas Pharma focused on discovering novel targets in the field of CNS disorders. BioFocus will utilize its SilenceSelect target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration. Financial terms were not disclosed.

“We are delighted to support Astellas Pharma in its research,” said Dr. Chris Newton, senior vice president Galapagos Services and managing director BioFocus. “Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology.”